Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 billion through 2027. Of that total, $4.5 billion in net cost savings will be ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk. Metsera, based in New York, is developing oral ...